Researchers at St. Jude Children’s Research Hospital have identified why a histone mutation found broadly throughout the body drives cancer almost exclusively in the brainstem and other midline structures of the developing brain. The findings, published in Nature Communications, help explain why diffuse midline glioma (DMG) develops preferentially in these regions, a pediatric brain cancer for which effective treatments remain limited. [1][2]
Key Takeaways
- The H3.3 K27M histone mutation alters DNA packaging similarly across brain regions, but its effects on cell development differ depending on where in the brain a cell originates. [1][2]
- In brainstem progenitor cells, the mutation prolongs an immature, actively dividing state and disrupts developmental signaling pathways more strongly than it does elsewhere in the brain. [1][2]
- The findings point to potential avenues for developing region-specific treatments for DMG, an important challenge in pediatric neuro-oncology. [1][2].
A Tumor Defined by Where It Arises
DMG is a childhood brain tumor that develops in midline structures of the central nervous system, including the brainstem, thalamus, and spinal cord, and is most often associated with mutations in the H3.3 histone protein at a specific site, K27M. [1] The question has been why this mutation, which can alter how DNA is packaged and regulated in cells from many parts of the body, is associated with tumors that arise predominantly along the brain’s midline rather than in other regions. [1] Suzanne Baker, PhD, of St. Jude’s Comprehensive Cancer Center and the study’s corresponding author, described the anatomical restriction of the mutation’s oncogenic effect as one of its most striking features, given its broad molecular effects. [1]
Comparing Cells From Different Regions of the Brain
To investigate this selectivity, the research team focused on oligodendrocyte precursor cells (OPCs), the progenitor population that matures into myelin-producing cells and shares transcriptional features with DMG tumor cells. [2] The investigators compared OPCs isolated from the brainstem, a region where H3.3 K27M-driven tumors commonly form, with OPCs from the telencephalon, a region where such tumors are rare. [1][2] Using a conditional knock-in mouse model, along with in vitro culture systems that allowed the researchers to synchronize and track cell differentiation over time, the team examined how OPCs from the two regions responded to the mutation under the same experimental conditions. [1][2]
Co-first author Jared Andrews, PhD, of St. Jude’s Department of Developmental Neurobiology, explained that placing cells from the two regions in the same controlled culture environment allowed the researchers to distinguish inherent differences between brainstem and telencephalon progenitors and then examine how H3.3 K27M affected those differences as the cells differentiated. [1]
Intrinsic Differences, Then a Mutation That Exploits Them
Even without any mutation present, the study found that wild-type brainstem OPCs behave differently from their telencephalic counterparts: they proliferate more slowly and reach later stages of differentiation on a delayed timeline. [2] When H3.3 K27M was introduced, this difference became more pronounced. In brainstem-derived OPCs, the mutation extended the period during which cells remained immature and actively dividing, longer than in telencephalon-derived cells carrying the same mutation. [1][2] In vivo imaging of whole, cleared mouse brains supported this pattern, showing that the mutation increased proliferation broadly across the brain but produced its largest effects in the brainstem, midline, and hindbrain regions. [2]
The mutation also disrupted signaling pathways that guide cell identity and developmental timing, including the Bmp, Wnt, and Notch pathways, and did so more strongly in brainstem-derived progenitor cells than in cells from other regions. [1][2] At the chromatin level, the researchers linked this effect to a class of gene promoters marked by both active and repressive histone signals, known as bivalent promoters. The mutation preferentially activated these promoters by depleting a repressive mark while leaving an active one intact. These promoters were more likely to overlap with the mutation’s target genes in brainstem tissue than in tissue from other brain regions. [2]
Why the Mechanism Matters
Taken together, the findings support a model in which H3.3 K27M has different effects depending on the cell’s developmental state. In brainstem progenitors, the mutation prolongs an immature, proliferative state and disrupts developmental signaling more strongly than it does in progenitors from other regions.[1][2] Baker noted that similar developmental differences may influence how other pediatric brain tumors arise and behave, not only DMG. Understanding these regional and developmental differences may therefore help guide future research into childhood brain cancers. [1]
What Remains Open
The study characterizes how the mutation alters cell proliferation, differentiation timing, and chromatin state in a region-dependent manner, but it does not identify a treatment that can reverse these effects. Nor does it establish that targeting the developmental signaling pathways implicated in the brainstem, such as Bmp, Wnt, or Notch, would be safe or effective in patients. The work was conducted in a genetically engineered mouse model and in primary mouse cell cultures. Whether these region-specific findings apply to human DMG biology, despite support from comparisons with previously published human tumor datasets, will require further validation in patient-derived material.
References
[1] St. Jude Children’s Research Hospital. Findings demonstrate how mutation disrupts cell development, driving region-specific brain tumors. Press release, August 26, 2026.
[2] Andrews JM, Budd KM, Kwon CH, Larson JD, Shirinifard A, Kasper LH, Williams CC, Lavado A, King S, Gutierrez J, Stabley D, Lin T, Lewis SA, Northcott PA, Onar-Thomas A, Baker SJ. Cell autonomous regional differences in oligodendrocyte lineage development and responses to oncohistone H3.3 K27M. Nat Commun.2026 Aug 26;17:8811. doi: 10.1038/s41467-026-76468-6.
This article is intended for informational purposes for healthcare professionals and does not constitute medical advice. Diffuse midline glioma remains a disease without an FDA-approved, disease-modifying treatment, and the findings described here are preclinical.
Featured image: (L to R) Co-first authors, Jared Andrews, PhD, and Chang-Hyuk Kwon, PhD, and corresponding author Suzanne Baker, PhD, St. Jude Department of Developmental Neurobiology. © 2026. St Jude Children’s Research Hospital. Used with permission.
DOI
